BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig 2017;37:61-70. [PMID: 27587071 DOI: 10.1007/s40261-016-0458-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Fan HZ, Huang P, Shao JG, Tian T, Li J, Zang F, Liu M, Xue H, Wu JJ, Yu RB, Zhang Y, Yue M. Genetic variation on the NFKB1 genes associates with the outcomes of HCV infection among Chinese Han population. Infect Genet Evol 2018;65:210-5. [PMID: 30056167 DOI: 10.1016/j.meegid.2018.07.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS One 2017;12:e0167770. [PMID: 28060834 DOI: 10.1371/journal.pone.0167770] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
3 Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. J Comp Eff Res 2018;7:785-95. [PMID: 29860879 DOI: 10.2217/cer-2018-0005] [Reference Citation Analysis]
4 Asker B, Jawad R, Asreah R, Jamal H, Jassem A, Inaya MA, Baker HA, Kozma S, Mansour E, McNamara B, Miller R, Darlington O, McEwan P, Sugrue DM, Jarallah H. Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment. Pharmacoeconomics 2021. [PMID: 34396494 DOI: 10.1007/s40273-021-01064-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bashir MH, Fazili J, Madhoun MF, Kanagala R, Chen S, Nusrat S. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. Eur J Gastroenterol Hepatol 2018;30:296-301. [PMID: 29200006 DOI: 10.1097/MEG.0000000000001032] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C. The Elimination of Hepatitis C as a Public Health Threat. Cold Spring Harb Perspect Med 2020;10:a036939. [PMID: 31712223 DOI: 10.1101/cshperspect.a036939] [Reference Citation Analysis]
7 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]